Key Takeaways
- Wolfe Research elevated both pharmaceutical companies to Outperform status, assigning each a $300 price objective
- The firm highlighted Biogen’s promising late-stage candidates litifilimab and felzartamab as significant value drivers
- Extended patent exclusivity for AbbVie’s Rinvoq through 2037 eliminates immediate concerns about generic competition
- AbbVie delivered second-quarter sales of $16.99 billion, representing a 10.2% year-over-year increase and surpassing Wall Street projections
- Biogen exceeded Q2 profit expectations with earnings per share of $3.60 compared to analyst forecasts of $2.94
Investment research firm Wolfe Research elevated both Biogen and AbbVie to Outperform status this past Thursday, establishing identical $300 price objectives for the pharmaceutical companies. The analyst firm’s optimistic stance stems from promising drug pipelines, compelling market valuations, and anticipated clinical trial results.
Biogen’s Advanced Pipeline Drives Positive Outlook
Biogen shares have been changing hands at a valuation discount compared to broader market indices, a pricing gap that Wolfe Research believes fails to account for the company’s developmental drug portfolio. The research firm upgraded its stance from Peer Perform while establishing a $300 price objective.
The investment thesis centers on two experimental therapies. Litifilimab has the potential to become the inaugural biologic treatment authorized for cutaneous lupus erythematosus. Meanwhile, felzartamab could serve patients experiencing antibody-mediated rejection in a commercial opportunity that exceeds current Street expectations.
The company’s acquisition of Apellis Pharmaceuticals bolsters its immediate revenue foundation with two commercially available medications, Empaveli and Syfovre.
During its latest quarterly report, the biotech firm surpassed profit projections. Earnings per share reached $3.60 versus analyst expectations of $2.94, while quarterly sales totaled $2.74 billion, marking a 3.4% year-over-year advancement. Management has established full-year 2026 earnings guidance between $12.00 and $13.00 per share.
Institutional investors control 87.93% of Biogen’s outstanding shares. Handelsbanken Fonder expanded its position by 12.7% during the second quarter, accumulating 93,236 shares valued at approximately $20.14 million.
Wall Street analysts maintain a Moderate Buy consensus on the stock, with an average target price of $224.61. Shares began trading Thursday at $208.87, approaching the 52-week peak of $219.72.
Extended Patent Timeline and Expanding Revenue Fuel AbbVie Upgrade
Wolfe similarly upgraded AbbVie from Peer Perform to Outperform status. The research team argues that AbbVie’s 2027 earnings valuation of 14.6 times appears undervalued for an organization projected to generate high-single-digit revenue expansion throughout the remainder of this decade.
Extended intellectual property protection represents a critical factor behind the upgrade. Generic competition for Rinvoq has been delayed until 2037, while AbbVie actively defends Skyrizi’s patent position. This scenario could enable the pharmaceutical giant to avoid significant patent expirations during the current decade.
The company announced second-quarter sales of $16.99 billion, climbing 10.2% year over year and exceeding consensus projections of $16.80 billion. Earnings per share registered at $3.65, marginally above the $3.61 estimate.
Skyrizi and Rinvoq continue serving as primary growth engines. Additionally, Canada’s Drug Agency has endorsed reimbursement coverage for Ubrelvy in acute migraine therapy, creating another potential revenue channel.
Shareholder approval of the Apogee Therapeutics acquisition adds approximately $8 billion to the company’s debt load, which certain analysts identify as an execution challenge.
AbbVie holds a consensus Moderate Buy rating among analysts with an average target price of $274.33. The stock commenced trading Thursday at $249.12.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
